Tandem autologous hematopoietic stem cell transplantation for embryonal brain tumors in infants and very young children

Геворгян, А. Г.; Kozlov, Andrey V.; Толкунова, П. С.; Казанцев, И. В.; Yukhta, T. V.; Morozova, Еlena V.; Punanov, Yuri A.; Zheludkova, Olga; Zubarovskaya, L.S.

doi:10.1038/s41409-022-01593-x

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the general transplant landscape, the RM Gorbacheva Research Institute has an active autoHCT program in pediatric solid tumors. If, in the early years, most of the patients with solid tumors were adults, with breast cancer and several others, then in recent years, only brain tumors and soft tissue tumors in children remained as indications [23]. The revealed tendency to reduce the proportion of acute leukemias as an indication for autoHCT is typical for most centers [24].…”

Section: Discussionmentioning

confidence: 99%

Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience

Zubarovskaya,

Moiseev,

Vladovskaya

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).

show abstract

Section: Discussionmentioning

confidence: 99%